Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Knee cartilage repair: your own cells could be the key

NCT ID NCT04296487

Disease control Sponsor: Centre Hospitalier Universitaire Vaudois Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a procedure called autologous chondrocyte implantation (ACI) for people with knee cartilage defects. Doctors take a sample of the patient's own cartilage cells, grow them in a lab, and then implant them into the damaged area. The goal is to see if this approach is safe and effective at repairing the knee and improving function. The trial is currently recruiting 218 participants aged 15 to 50.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous chondrocytes (patient's own cartilage cells)
What this could lead to
If successful, this could offer a safe and effective way to repair knee cartilage damage, potentially reducing pain and improving mobility.
What could go wrong
This is an early-stage study focused on safety and feasibility. The procedure may not work for everyone, and risks include infection, inflammation, or incomplete healing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2017

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 15 and 50. 2. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2 3. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months) 4. Subjects who understand and sign the consent form for this study Exclusion Criteria: 1. Body mass index (BMI) of 35 or more 2. Osteoarthritis or rheumatoid arthritis 3. Diffuse lesion 4. Uncorrected mal-alignment, ligamentous instability, or meniscal tear 5. Presence of growth cartilage (15-18 years old) 6. Active smoking or drug consumption 7. Women who are pregnant 8. Positive serology for HIV-1 or HIV-2, Hepatitis B and C and syphilis 9. Proven allergy to porcine collagen, penicillin and gentamicin 10. Poor compliance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Articular cartilage defect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

articular cartilage disorder chondromalacia Osteochondritis osteochondrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Articular cartilage defect Chondral defect Osteochondritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois - CHUV

    RECRUITING

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.